[ Back ]
From: NIH - CAM Office
Date: 8/17/2002
Time: 4:35:42 PM
Remote Name: 207.144.211.45
2. DEVELOPMENTAL /PILOT PROJECTS IN CANCER COMPLEMENTARY AND ALTERNATIVE MEDICINE (CAM) This Program Announcement expires on October 22, 2003, unless reissued. DEVELOPMENTAL /PILOT PROJECTS IN CANCER COMPLEMENTARY AND ALTERNATIVE MEDICINE (CAM) Release Date: December 17, 2001 PA NUMBER: PAR-02-040 National Cancer Institute (http://cancer.gov/ National Center for Complementary and Alternative Medicine (http://nccam.nih.gov/ Letter of Intent Dates: January 16, 2002, May 17, 2002, September 16, 2002, January 16, 2003, May 23, 2003, September 16, 2003 Application Receipt Dates: February 20, 2002, June 21, 2002, October 21, 2002, February 20, 2003, June 20, 2003, October 21, 2003 THIS PA USES "MODULAR GRANT" AND "JUST-IN-TIME" CONCEPTS. MODULAR INSTRUCTIONS MUST BE USED FOR RESEARCH GRANT APPLICATIONS REQUESTING LESS THAN $250,000 PER YEAR IN ALL YEARS. MODULAR BUDGET INSTRUCTIONS ARE PROVIDED IN SECTION C OF THE PHS 398 (REVISION 5/2001) AVAILABLE AT http://grants.nih.gov/grants/funding/phs398/phs398.html PURPOSE The Office of Cancer Complementary and Alternative Medicine of the National Cancer Institute (NCI), and the National Center for Complementary and Alternative Medicine (NCCAM) invite research grant applications from interested investigators to conduct innovative developmental pilot research investigating Complementary and Alternative Medicine (CAM) in cancer. The intent of this initiative is to encourage and support the development of basic and clinical CAM cancer research and to provide the basis for more extended research projects by establishing the methodological feasibility and strengthening the scientific rationale for these projects. This announcement is also intended to stimulate and facilitate the entry of promising investigators into cancer CAM research through a program of exploratory investigator-initiated R21 grants. The exploratory/developmental (R21) grant mechanism is used for pilot projects or feasibility studies to support the exploration of feasibility, as well as the development, of projects investigating CAM in cancer and for the generation of preliminary data. The R21 mechanism is specifically intended to support innovative ideas where preliminary data are sparse or do not exist. The R21 supported projects are intended to serve as a foundation for planning and developing future research projects (R01s). The objective of this Program Announcement (PA) is to encourage applications from individuals who are interested in testing novel or conceptually creative ideas that may produce innovative advances in the understanding and use of CAM in cancer. RESEARCH OBJECTIVES [...] There is a paucity of R01 funded research grants in the field of cancer CAM. Therefore, to increase the number and quality of investigator-initiated R01 research grants on cancer CAM, the NCI's Office of Cancer Complementary and Alternative Medicine and NCCAM developed this PA for Developmental/Pilot Projects in Cancer CAM. Applications will undergo competitive review organized by the NCCAM in collaboration with the NCI. The intent of this initiative is to encourage and support the development of basic, and clinical (prevention, therapeutic and palliative) CAM cancer research. Another goal of this initiative is to facilitate communication and collaboration between the CAM practitioner and the conventional cancer research communities. For the purpose of this PA, applicants must include modalities from the following broad program areas in CAM: Alternative Medical Systems (e.g., oriental medicine, Ayurvedic, homeopathy, naturopathy); Manipulative and Body-based Systems (e.g., chiropractic, osteopathic, massage therapy or unconventional applications of integrated conventional and physical therapies); Energy Therapies. These approaches focus either on energy fields purported to originate within or be conducted through the body (e.g., external qi gong, therapeutic touch, Reiki, intentional effects on living systems); or those from other sources [e.g., therapeutic application of electromagnetic (EM) fields including pulsed EM fields, magnetic fields, Direct Current (DC) fields]. Pharmacological or Biologically based Therapies (e.g., metabolic therapies and immunoaugmentative therapies as used by CAM practitioners or the public such as Coley's toxin, Enzyme therapies, the Livingston-Wheeler system, the Revici system, or 714-X ) Herbal Medicine (Note: This category includes studies of whole plant products or extracts and does not include the study or isolation of active ingredients from herbal preparations except where identification and standardization of optimal whole product are the specific aim -- e.g. optimal ratio of glycosides and terpenoids in Ginkgo biloba -- or comparisons are being made to the whole product); Orthomolecular Medicine - This category includes the use of nutritional and food supplements, Co-enzyme Q10, carnitine, melatonin, vitamins) for therapeutic or preventive purposes. These products are usually used in combinations and at very high doses (5-10 fold) well above the Recommended Daily Allowance (RDA) when such RDAs have been defined. Mind-Body Medicine: Concept proposals in this category will be considered only if they are limited to those mind-body approaches that are used by the public or practitioners outside of a conventional medicine setting (e.g., transcendental meditation, imagery, hypnosis, biofeedback, music therapy, yoga, relaxation, spirituality, biological effects of consciousness). Mind- body approaches that are relatively integrated into conventional medicine (e.g., patient education, psychotherapy, cognitive-behavioral approaches, etc.) will NOT be considered unless physiologic endpoints (e.g., immune parameters) or disease parameters (response rate to conventional therapy, disease-free survival, overall survival) are the primary outcome measures; Applications may also focus on interactions between these modalities and non- CAM cancer treatment and therapies (e.g. Drug Interactions: studies to evaluate the potential interaction of antioxidant compounds and conventional chemotherapy and/or radiation therapy.) ELIGIBILITY REQUIREMENTS Applications may be submitted by foreign and domestic, for-profit and not- for-profit organizations, public and private, such as universities, colleges, hospitals, laboratories, units of State and local governments, and eligible agencies of the Federal government. Racial/ethnic minority individuals, women, and persons with disabilities are encouraged to apply as principal investigators. INQUIRIES Inquiries are strongly encouraged. The opportunity to clarify any issues or questions from potential applicants is welcome. Direct inquiries regarding programmatic issues to: Wendy B. Smith, Ph.D. Office of Cancer Complementary and Alternative Medicine National Cancer Institute Executive Plaza North 6130 Executive Blvd Suite #102, MSC 7302 Bethesda, MD 20892-7302 Telephone: (301) 435-7980 FAX: (301) 480-0075 Email: smithwe@mail.nih.gov Mary Ann Richardson, DrPH National Center for Complementary and Alternative Medicine 6707 Democracy Blvd, Suite 102 Bethesda, MD 20892-5475 Telephone: (301) 402-1272 FAX: (301) 480-3621 Email: marich@mail.nih.gov Direct inquiries regarding fiscal matters to: Ms. Eileen Natoli Grants Administration Branch National Cancer Institute EPS-Room 243 Bethesda, Maryland 20892 Telephone: (301) 496-8791 FAX: (301) 496-8601 Email: natolie@gab.nci.nih.gov Direct inquiries regarding review matters to: NCI Referral Officer Division of Extramural Activities National Cancer Institute 6116 Executive Boulevard, Room 8109, MSC 8329 Bethesda, MD 20892-8329 Rockville, MD 20852 (for express/courier service) Telephone: (301) 496-3428 Fax: (301) 402-0275 Email: ncidearefof-r@mail.nih.gov Dr. Martin Goldrosen Office of Review National Center for Complementary and Alternative Medicine 6707 Democracy Blvd., Suite 106 MSC 5475 Bethesda, Maryland 20892-5475 Telephone: (301) 496-4792 Fax: (301) 480-2419 Email: goldrosm@mail.nih.gov [...] For full text of announcement, please see http://grants1.nih.gov/grants/guide/pa-files/PAR-02-040.html